These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29808571)

  • 1. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review.
    Vilela RA; Navarro NF; Faria ET; Ferreira EB; Ruzza RZ; Gadia R; Guerra ENS; Reis PEDD
    J Med Imaging Radiat Oncol; 2018 Oct; 62(5):692-706. PubMed ID: 29808571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
    Zhang B; Leech M
    Anticancer Res; 2020 May; 40(5):2419-2428. PubMed ID: 32366385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience.
    Ponti E; Ingrosso G; Carosi A; Di Murro L; Lancia A; Pietrasanta F; Santoni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):e279-e284. PubMed ID: 25604915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
    Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
    Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.
    Ingrosso G; Trippa F; Maranzano E; Carosi A; Ponti E; Arcidiacono F; Draghini L; Di Murro L; Lancia A; Santoni R
    World J Urol; 2017 Jan; 35(1):45-49. PubMed ID: 27233779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
    Ost P; Jereczek-Fossa BA; Van As N; Zilli T; Tree A; Henderson D; Orecchia R; Casamassima F; Surgo A; Miralbell R; De Meerleer G
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e115-20. PubMed ID: 27133946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
    BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.
    Berkovic P; De Meerleer G; Delrue L; Lambert B; Fonteyne V; Lumen N; Decaestecker K; Villeirs G; Vuye P; Ost P
    Clin Genitourin Cancer; 2013 Mar; 11(1):27-32. PubMed ID: 23010414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Stereotactic Body Radiotherapy With Immediate Versus Delayed Hormone Therapy in Men With Oligometastatic Recurrence of Prostate Cancer.
    Chaw CL; deSouza NM; Khoo V; Suh YE; van As N
    Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):509-517. PubMed ID: 32423621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
    Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
    BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
    Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
    Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Stereotactic body radiation therapy for oligometastatic prostate cancer].
    Bibault JE
    Bull Cancer; 2018 Jan; 105(1):120-125. PubMed ID: 29191358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.
    Jereczek-Fossa BA; Fanetti G; Fodor C; Ciardo D; Santoro L; Francia CM; Muto M; Surgo A; Zerini D; Marvaso G; Timon G; Romanelli P; Rondi E; Comi S; Cattani F; Golino F; Mazza S; Matei DV; Ferro M; Musi G; Nolè F; de Cobelli O; Ost P; Orecchia R
    Clin Genitourin Cancer; 2017 Aug; 15(4):e623-e632. PubMed ID: 28185875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
    Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
    Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
    Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.
    Decaestecker K; De Meerleer G; Ameye F; Fonteyne V; Lambert B; Joniau S; Delrue L; Billiet I; Duthoy W; Junius S; Huysse W; Lumen N; Ost P
    BMC Cancer; 2014 Sep; 14():671. PubMed ID: 25223986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.
    Niazi T; Elakshar S; Stroian G
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):351-358. PubMed ID: 29979320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.